dosing commenced, page-7

I'm so pleased to see this technology deployed. We of course have CalImmune using this technology with an out-of-body transfection -- but to gain the trust and confidence to do an in-body genetic modification and do it safely is substantial.

Clock is now ticking -- the earliest possible hint of efficacy is 30 weeks from now (first two dose levels expected to be well below therapeutic level). That is 25 Dec 2014. And only if the company is able to release information as the trial proceeds.

Earliest date for trial completion: 12 Nov 2015.

I'll be aiming to buy into this company again in 2015.